Page last updated: 2024-09-03

xaliproden and Allergic Encephalomyelitis

xaliproden has been researched along with Allergic Encephalomyelitis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bourrié, B; Bribes, E; Casellas, P; Esclangon, M; Garcia, L; Maffrand, JP; Marchand, J; Thomas, C	1

Other Studies

1 other study(ies) available for xaliproden and Allergic Encephalomyelitis

Article	Year
The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment. Proceedings of the National Academy of Sciences of the United States of America, 1999, Oct-26, Volume: 96, Issue:22 Topics: Administration, Oral; Animals; Blood-Brain Barrier; Cytokines; Encephalomyelitis, Autoimmune, Experimental; Female; Lipopolysaccharides; Multiple Sclerosis; Naphthalenes; Neuroprotective Agents; Pyridines; Rats; Rats, Inbred Lew; Th1 Cells; Th2 Cells; Tumor Necrosis Factor-alpha	1999

Article

Year

The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment.

Proceedings of the National Academy of Sciences of the United States of America, 1999, Oct-26, Volume: 96, Issue:22

Topics: Administration, Oral; Animals; Blood-Brain Barrier; Cytokines; Encephalomyelitis, Autoimmune, Experimental; Female; Lipopolysaccharides; Multiple Sclerosis; Naphthalenes; Neuroprotective Agents; Pyridines; Rats; Rats, Inbred Lew; Th1 Cells; Th2 Cells; Tumor Necrosis Factor-alpha

1999